NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 216 filers reported holding NEKTAR THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,995 | +285.7% | 119,200 | +272.5% | 0.00% | – |
| Q2 2023 | $18,405 | +5.2% | 32,000 | +28.5% | 0.00% | – |
| Q1 2023 | $17,501 | -93.8% | 24,900 | -80.0% | 0.00% | -100.0% |
| Q4 2022 | $281,829 | -58.6% | 124,703 | -41.3% | 0.00% | -66.7% |
| Q3 2022 | $680,000 | +129.0% | 212,417 | +171.6% | 0.01% | +100.0% |
| Q2 2022 | $297,000 | -46.2% | 78,200 | +91.6% | 0.00% | -40.0% |
| Q4 2021 | $552,000 | -85.0% | 40,810 | -80.1% | 0.01% | -87.2% |
| Q3 2021 | $3,687,000 | +265.0% | 205,309 | +249.0% | 0.04% | +254.5% |
| Q2 2021 | $1,010,000 | +4.8% | 58,829 | +22.1% | 0.01% | -8.3% |
| Q1 2021 | $964,000 | -60.7% | 48,199 | -54.5% | 0.01% | -63.6% |
| Q2 2020 | $2,456,000 | +170.8% | 106,014 | +112.9% | 0.03% | +22.2% |
| Q3 2019 | $907,000 | -59.0% | 49,800 | +139.4% | 0.03% | -83.7% |
| Q1 2018 | $2,211,000 | +489.6% | 20,804 | -4.6% | 0.17% | +159.4% |
| Q3 2016 | $375,000 | – | 21,803 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 432,952 | $1,385,000 | 0.91% |
| GREAT POINT PARTNERS LLC | 447,820 | $1,433,000 | 0.34% |
| Birchview Capital, LP | 128,000 | $410,000 | 0.29% |
| Edgestream Partners, L.P. | 1,047,636 | $3,352,000 | 0.26% |
| Rhenman & Partners Asset Management AB | 550,000 | $2,068,000 | 0.22% |
| CM Management, LLC | 50,000 | $160,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 430,037 | $1,376,000 | 0.17% |
| PDT Partners, LLC | 307,953 | $985,000 | 0.15% |
| Virtus ETF Advisers LLC | 72,018 | $230,000 | 0.09% |
| ALGERT GLOBAL LLC | 476,412 | $1,525,000 | 0.09% |